SCHEMBL23294805

SCHEMBL23294805

CN(C)C1CCN(c2ccc(-c3ccc4nc5cccc(N6CCOCC6)c5n4c3)cc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 3/20 0.39
▸ ALOX5 P09917 4/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ PDCD1 Q15116 1/20 0.38
▸ CD274 Q9NZQ7 1/20 0.38
▸ EGFR P00533 1/20 0.37
▸ GAA P10253 5/20 0.37
▸ MAPT P10636 5/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ EIF4E P06730 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ MKNK1 Q9BUB5 1/20 0.37
▸ MKNK2 Q9HBH9 1/20 0.37
▸ TP53 P04637 3/20 0.36
▸ RAD51 Q06609 1/20 0.36
▸ AHR P35869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23294861 0.95 KCNH2 (0.37) PIK3CAPDCD1CD274EIF4EKCNH2
SCHEMBL23294863 0.88 CNR2 (0.41) PIK3CAKCNH2MTOR
SCHEMBL23294811 0.86 MET (0.36) PIK3CAPDCD1CD274EIF4EKCNH2
SCHEMBL23294875 0.82 MAOB (0.38) PIK3CAPDCD1CD274EGFREIF4E
SCHEMBL23294788 0.82 PIK3CD (0.37) PIK3CAPDCD1CD274EIF4EKCNH2
SCHEMBL23294818 0.82 PIK3CA (0.37) PIK3CAPDCD1CD274EIF4EKCNH2
SCHEMBL23294800 0.81 PIK3CA (0.34) PIK3CAALOX5EPHX2PDCD1CD274
SCHEMBL23294917 0.80 PIK3CA (0.36) PIK3CAPDCD1CD274EIF4EKCNH2
SCHEMBL23294859 0.79 PARP1 (0.43) EIF4EKCNH2MKNK1MKNK2
SCHEMBL23294867 0.77 PARP1 (0.44) PIK3CAPIK3CDSLC2A1PIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof Impact Therapeutics (Shanghai), Inc (CN) 2023-01-10 — — US claimed
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2021-05-06 — — US claimed
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof Impact Therapeutics (Shanghai), Inc (CN) 2023-01-10 — — US disclosed
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof CHEK2, CHEK1, ATM PIK3CA 93/4885ALOX5 4851/4885EPHX2 3909/4885
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof CHEK2, CHEK1, ATM PIK3CA 93/4885ALOX5 4851/4885EPHX2 3909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback